Motley Fool Australia

Why the Australian Pharmaceutical Industries Ltd share price is plunging

Credit: Priceline

Healthcare stock Australian Pharmaceutical Industries Ltd (ASX: API) is at the top of the S&P/ASX 200 declines today after the release of its earnings results last week revealed a flat revenue and shrinking sales in its Priceline brand.

Credit Suisse has placed a neutral rating on the stock with the broker saying the short-term outlook for the company is “challenging” and Australian Pharmaceutical Industries shares are down 4.2% at the time of writing to $1.36.

The broker believes the conversion of independent pharmacies to the Priceline model could see an increase in operating leverage but PBS reforms could prove problematic as some manufacturers choose to bypass wholesale distributors and go direct to pharmacies.

Credit Suisse has reduced its price target on the stock from $1.62 to $1.50.

In the healthcare space Sigma Healthcare Ltd (ASX: SIG) has also signalled struggles with PBS changes with its Hepatitis C medicines with Sigma shares down at the time of writing to 73c per share.

Mayne Pharma Group Ltd (ASX: MYX) shares have recovered slightly today with a gain of 0.7% to 69c per share at the time of writing after a week of falls.

Our TOP healthcare stock is trading at a 30% discount to its highs

If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.

Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.

Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!

As of 2.11.2020

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles…